Skip to main content
. 2022 Jun 13;12(6):e848. doi: 10.1002/ctm2.848

FIGURE 6.

FIGURE 6

YTHDF2 facilitates the ICC progression and cisplatin resistance by modulating CDKN1B mRNA decay. (A) Relative mRNA expression of CDKN1B in HuCC‐T1 and HCCC‐9810 cells transfected with siControl or siCDKN1B for 48 h. (B) Cell viability of HuCC‐T1 and HCCC‐9810 cells transfected with siControl or siCDKN1B for 48 h. (C) Cell viability of HuCC‐T1 and HCCC‐9810 cells co‐transfected with indicated shRNA or/and siRNA for 48 h. (D) Apoptosis analysis of HuCC‐T1 and HCCC‐9810 cells co‐transfected with indicated shRNA or/and siRNA for 48 h. (E) Cell cycle analysis of HuCC‐T1 and HCCC‐9810 cells co‐transfected with indicated shRNA or/and siRNA for 48 h. (F) Immunoblotting to measure CDK2 and CDK4 protein levels in HuCC‐T1 and HCCC‐9810 cells co‐transfected with indicated shRNA or/and siRNA for 48 h. (G) Representative flow cytometry analysis and mean fluorescent intensity of γ‐H2AX in indicated shRNA or/and siRNA co‐transfected HuCC‐T1 and HCCC‐9810 cells after treatment with cisplatin (20 or 10 μM, respectively). (H) Immunoblotting to measure caspase‐9, cleaved caspase‐9, caspase‐3, cleaved caspase‐3 protein levels in indicated shRNA or/and siRNA co‐transfected HuCC‐T1 and HCCC‐9810 cells after treatment with cisplatin (60 or 40 μM, respectively). The data are presented as mean ± SD and compared by t‐test. *p < .05; **p < .01; *** p < .001